

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



# 廣州藥業股份有限公司

**Guangzhou Pharmaceutical Company Limited**

*(a joint stock company with limited liability established in the People's Republic of China)*

(H Share Stock Code: 0874)

## ANNOUNCEMENT

Guangzhou Pharmaceutical Company Limited (the “Company”) has been informed that Guangzhou Pharmaceutical Holdings Limited (“GPHL”), the controlling shareholder of the Company, received an arbitration notice (the “Notice”)【(2012)-Zhongguomaozhongjingzi No.015198】 (【(2012)中國貿仲京字第015198號】) for a trademark license agreement dispute No.X20120416 from the China International Economic and Trade Arbitration Commission (the “Commission”) dated 31 July 2012. According to the Notice, Hung To (Holdings) Company Limited had made application for arbitration to the Commission on the dispute of the trademark license agreement entered into between Hung To (Holdings) Company Limited and GPHL on 2 May 2003.

The board of the directors of the Company (the “Board”) confirms that, other than the Notice, it is not in possession of information which the Company is required to disclose under the listing rules of the Shanghai Stock Exchange or Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“Hong Kong Listing Rules”), nor is the Board aware of any information which may have any significant impact on the Company’s share price and is therefore discloseable under the listing rules of the Shanghai Stock Exchange or Hong Kong Listing Rules.

The Company’s designated media for publication of its information includes Shanghai Securities News, Securities Times, the website of the Shanghai Stock Exchange (<http://www.sse.com.cn>) and the website of The Stock Exchange of Hong Kong Limited (<http://www.hkex.com.hk>). Investors are advised to pay attention to investment risks.

This announcement is made pursuant to Rule 13.09(2) of the Hong Kong Listing Rules.

The Board of  
**Guangzhou Pharmaceutical Company Limited**

Guangzhou, the PRC, 6 August 2012

*As at the date of this announcement, the Board comprises Mr. Yang Rongming, Mr. Li Chuyuan and Mr. Wu Changhai as executive directors, and Mr. Liu Jinxiang, Mr. Li Shanmin, Mr. Zhang Yonghua, Mr. Wong Lung Tak Patrick and Mr. Qiu Hongzhong as independent non-executive directors.*